Literature DB >> 1479602

Deficiencies of fibrillin and decorin in fibroblast cultures of a patient with neonatal Marfan syndrome.

A Superti-Furga1, M Raghunath, P J Willems.   

Abstract

Changes in the structure and metabolism of fibrillin, a microfibril associated protein, can result in classical Marfan syndrome, and reduced expression of decorin, a small extracellular chondroitin sulphate/dermatan sulphate proteoglycan, has been observed in fibroblasts of a patient with neonatally lethal Marfan syndrome. We have studied the synthesis of fibrillin and decorin in cultured fibroblasts of a further sporadic patient with neonatally lethal Marfan syndrome. Fibrillin immunoreactivity in the extracellular matrix of the patient's fibroblasts was markedly reduced, and the fibrillar pattern was absent, in spite of normal amounts of fibrillin mRNA. Decorin mRNA, synthesis, and immunoreactivity in the matrix were also reduced. The results indicate involvement of both fibrillin and decorin in the pathogenesis of neonatal Marfan syndrome in this patient, but do not indicate which is the primary defect. We speculate, however, that a structural defect of fibrillin leads to diminished incorporation of the protein into the extracellular matrix, and that underexpression of decorin is secondary to the primary fibrillin defect. Combined deficiency of fibrillin and decorin may be the cause of the severe clinical phenotype.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1479602      PMCID: PMC1016204          DOI: 10.1136/jmg.29.12.875

Source DB:  PubMed          Journal:  J Med Genet        ISSN: 0022-2593            Impact factor:   6.318


  18 in total

Review 1.  Proteoglycans as modulators of growth factor activities.

Authors:  E Ruoslahti; Y Yamaguchi
Journal:  Cell       Date:  1991-03-08       Impact factor: 41.582

2.  Differential regulation of extracellular matrix proteoglycan (PG) gene expression. Transforming growth factor-beta 1 up-regulates biglycan (PGI), and versican (large fibroblast PG) but down-regulates decorin (PGII) mRNA levels in human fibroblasts in culture.

Authors:  V M Kähäri; H Larjava; J Uitto
Journal:  J Biol Chem       Date:  1991-06-05       Impact factor: 5.157

3.  Marfan syndrome: defective synthesis, secretion, and extracellular matrix formation of fibrillin by cultured dermal fibroblasts.

Authors:  D M Milewicz; R E Pyeritz; E S Crawford; P H Byers
Journal:  J Clin Invest       Date:  1992-01       Impact factor: 14.808

4.  Marfan syndrome caused by a recurrent de novo missense mutation in the fibrillin gene.

Authors:  H C Dietz; G R Cutting; R E Pyeritz; C L Maslen; L Y Sakai; G M Corson; E G Puffenberger; A Hamosh; E J Nanthakumar; S M Curristin
Journal:  Nature       Date:  1991-07-25       Impact factor: 49.962

5.  Partial sequence of a candidate gene for the Marfan syndrome.

Authors:  C L Maslen; G M Corson; B K Maddox; R W Glanville; L Y Sakai
Journal:  Nature       Date:  1991-07-25       Impact factor: 49.962

6.  Immunohistologic abnormalities of the microfibrillar-fiber system in the Marfan syndrome.

Authors:  D W Hollister; M Godfrey; L Y Sakai; R E Pyeritz
Journal:  N Engl J Med       Date:  1990-07-19       Impact factor: 91.245

7.  Non-uniform influence of transforming growth factor-beta on the biosynthesis of different forms of small chondroitin sulphate/dermatan sulphate proteoglycan.

Authors:  B Breuer; G Schmidt; H Kresse
Journal:  Biochem J       Date:  1990-07-15       Impact factor: 3.857

8.  The Wiedemann-Rautenstrauch or neonatal progeroid syndrome. Report of a patient with consanguineous parents.

Authors:  E A Devos; J G Leroy; J P Frijns; H Van den Berghe
Journal:  Eur J Pediatr       Date:  1981-07       Impact factor: 3.183

9.  Neonatal Marfan syndrome with congenital arachnodactyly, flexion contractures, and severe cardiac valve insufficiency.

Authors:  I M Buntinx; P J Willems; S E Spitaels; P J Van Reempst; A M De Paepe; J E Dumon
Journal:  J Med Genet       Date:  1991-04       Impact factor: 6.318

10.  Recurrent ctb(7)(q31.3) and possible laminin involvement in a neonatal cutis laxa with a Marfan phenotype.

Authors:  D Bonneau; J L Huret; G Godeau; D Couet; M Putterman; J Tanzer; P Babin; M Larrègue
Journal:  Hum Genet       Date:  1991-07       Impact factor: 4.132

View more
  7 in total

Review 1.  The molecular genetics of Marfan syndrome and related microfibrillopathies.

Authors:  P N Robinson; M Godfrey
Journal:  J Med Genet       Date:  2000-01       Impact factor: 6.318

2.  Decorin-mediated regulation of fibrillin-1 in the kidney involves the insulin-like growth factor-I receptor and Mammalian target of rapamycin.

Authors:  Liliana Schaefer; Wasiliki Tsalastra; Andrea Babelova; Martina Baliova; Jens Minnerup; Lydia Sorokin; Hermann-Josef Gröne; Dieter P Reinhardt; Josef Pfeilschifter; Renato V Iozzo; Roland M Schaefer
Journal:  Am J Pathol       Date:  2007-01       Impact factor: 4.307

3.  Abnormal morphology of fibrillin microfibrils in fibroblast cultures from patients with neonatal Marfan syndrome.

Authors:  M Godfrey; M Raghunath; J Cisler; C L Bevins; A DePaepe; M Di Rocco; J Gregoritch; K Imaizumi; P Kaplan; Y Kuroki
Journal:  Am J Pathol       Date:  1995-06       Impact factor: 4.307

4.  A compound-heterozygous Marfan patient: two defective fibrillin alleles result in a lethal phenotype.

Authors:  L Karttunen; M Raghunath; L Lönnqvist; L Peltonen
Journal:  Am J Hum Genet       Date:  1994-12       Impact factor: 11.025

5.  Severe neonatal Marfan syndrome resulting from a de novo 3-bp insertion into the fibrillin gene on chromosome 15.

Authors:  D M Milewicz; M Duvic
Journal:  Am J Hum Genet       Date:  1994-03       Impact factor: 11.025

Review 6.  Distribution and Function of Glycosaminoglycans and Proteoglycans in the Development, Homeostasis and Pathology of the Ocular Surface.

Authors:  Sudan Puri; Yvette M Coulson-Thomas; Tarsis F Gesteira; Vivien J Coulson-Thomas
Journal:  Front Cell Dev Biol       Date:  2020-08-07

7.  Developmental abnormalities in the cornea of a mouse model for Marfan syndrome.

Authors:  Eleanor M Feneck; Rodrigo B Souza; Philip N Lewis; Sally Hayes; Lygia V Pereira; Keith M Meek
Journal:  Exp Eye Res       Date:  2020-03-13       Impact factor: 3.467

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.